NEW YORK – Interpace Biosciences said on Wednesday that it has received a delisting notice from the Nasdaq due to the firm's extended period of non-compliance with the minimum $2.5 million stockholder's equity requirement for continued listing and the firm's failure to timely execute on its plan to comply.